Mercedes Azucena Hernandez-Sapiens

Mrs. Mercedes Azucena Hernandez-Sapiens

Biotecnología Médica Farmacéutica, Centro de investigacion y asistencia en tecnologia y diseño del estado de Jalisco, Guadalajara, Jalisco, Mexico
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Neural Regeneration Research
Verified
Journal Article
Open access
PDF file
EREdwin E. Reza-Zaldivar
Edwin E. Reza-Zaldivar
MHMercedes Azucena Hernandez-Sapiens
Mercedes Azucena Hernandez-Sapiens
YGYanet Karina Gutierrez-Mercado
Yanet Karina Gutierrez-Mercado
SSSergio Sandoval-Ávila
Sergio Sandoval-Ávila
Ulises Gomez-PinedoUlises Gomez-Pinedo
Ulises Gomez-Pinedo
Alejandro CanalesAlejandro Canales
Alejandro Canales
Studies have shown that mesenchymal stem cell-derived exosomes can enhance neural plasticity and improve cognitive impairment. The purpose of this study was to investigate the effects of mesenchymal stem cell-derived exosomes on neurogenesis and cognitive capacity in a mouse model of Alzheimer’s disease. Alzheimer’s disease mouse models were established by injection of beta amyloid 1−42 aggregates into dentate gyrus bilaterally. Morris water maze and novel object recognition tests were performed to evaluate mouse cognitive deficits at 14 and 28 days after administration. Afterwards, neurogenesis in the subventricular zone was determined by immunofluorescence using doublecortin and PSA-NCAM antibodies. Results showed that mesenchymal stem cells-derived exosomes stimulated neurogenesis in the subventricular zone and alleviated beta amyloid 1−42-induced cognitive impairment, and these effects are similar to those shown in the mesenchymal stem cells. These findings provide evidence to validate the possibility of developing cell-free therapeutic strategies for Alzheimer’s disease. All procedures and experiments were approved by Institutional Animal Care and Use Committee (CICUAL) (approval No. CICUAL 2016-011) on April 25, 2016.

24 September 2018 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
EREdwin E. Reza-Zaldivar
Edwin E. Reza-Zaldivar
MHMercedes Azucena Hernandez-Sapiens
Mercedes Azucena Hernandez-Sapiens
BMBenito Minjarez
Benito Minjarez
YGYanet Karina Gutierrez-Mercado
Yanet Karina Gutierrez-Mercado
AMAna Laura Márquez-Aguirre
Ana Laura Márquez-Aguirre
Alejandro CanalesAlejandro Canales
Alejandro Canales
Alzheimer’s disease (AD) is the most common type of dementia affecting regions of the central nervous system that exhibit synaptic plasticity and are involved in higher brain functions such as learning and memory. AD is characterized by progressive cognitive dysfunction, memory loss and behavioral disturbances of synaptic plasticity and energy metabolism. Cell therapy has emerged as an alternative treatment of AD. The use of adult stem cells, such as neural stem cells and Mesenchymal Stem Cells (MSCs) from bone marrow and adipose tissue, have the potential to decrease cognitive deficits, possibly by reducing neuronal loss through blocking apoptosis, increasing neurogenesis, synaptogenesis and angiogenesis. These processes are mediated primarily by the secretion of many growth factors, anti-inflammatory proteins, membrane receptors, microRNAs (miRNA) and exosomes. Exosomes encapsulate and transfer several functional molecules like proteins, lipids and regulatory RNA which can modify cell metabolism. In the proteomic characterization of the content of MSC-derived exosomes, more than 730 proteins have been identified, some of which are specific cell type markers and others are involved in the regulation of binding and fusion of exosomes with adjacent cells. Furthermore, some factors were found that promote the recruitment, proliferation and differentiation of other cells like neural stem cells. Moreover, within exosomal cargo, a wide range of miRNAs were found, which can control functions related to neural remodeling as well as angiogenic and neurogenic processes. Taking this into consideration, the use of exosomes could be part of a strategy to promote neuroplasticity, improve cognitive impairment and neural replacement in AD. In this review, we describe how exosomes are involved in AD pathology and discuss the therapeutic potential of MSC-derived exosomes mediated by miRNA and protein cargo.

5 May 2020 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
EREdwin Estefan Reza-Zaldivar
Edwin Estefan Reza-Zaldivar
MHMercedes Azucena Hernandez-Sapiens
Mercedes Azucena Hernandez-Sapiens
BMBenito Minjarez
Benito Minjarez
Ulises Gomez-PinedoUlises Gomez-Pinedo
Ulises Gomez-Pinedo
VSVictor Javier Sánchez-González
Victor Javier Sánchez-González
Alejandro CanalesAlejandro Canales
Alejandro Canales
Dendrites and dendritic spines are dynamic structures with pivotal roles in brain connectivity and have been recognized as the locus of long-term synaptic plasticity related to cognitive processes such as learning and memory. In neurodegenerative diseases, the spine dynamic morphology alteration, such as shape and spine density, affects functional characteristics leading to synaptic dysfunction and cognitive impairment. Recent evidence implicates dendritic spine dysfunction as a critical feature in the pathogenesis of dementia, particularly Alzheimer’s disease. The alteration of spine morphology and their loss is correlated with the cognitive decline in Alzheimer’s disease patients even in the absence of neuronal loss, however, the underlying mechanisms are poorly understood. Currently, the microRNAs have emerged as essential regulators of synaptic plasticity. The changes in neuronal microRNA expression that contribute to the modification of synaptic function through the modulation of dendritic spine morphology or by regulating the local protein translation to synaptic transmission are determinant for synapse formation and synaptic plasticity. Focusing on microRNA and its targets may provide insight into new therapeutic opportunities. In this review we summarize the experimental evidence of the role that the microRNA plays in dendritic spine remodeling and synaptic plasticity and its potential therapeutic approach in Alzheimer’s disease. Targeting synaptic deficits through the structural alteration of dendritic spines could form part of therapeutic strategies to improve synaptic plasticity and to ameliorate cognitive impairments in Alzheimer’s disease and other neurological diseases.

12 June 2020 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
MHMercedes Azucena Hernandez-Sapiens
Mercedes Azucena Hernandez-Sapiens
EREdwin E. Reza-Zaldívar
Edwin E. Reza-Zaldívar
RCRicardo R. Cevallos
Ricardo R. Cevallos
AMAna L. Márquez-Aguirre
Ana L. Márquez-Aguirre
KGKarlen Gazarian
Karlen Gazarian
Alejandro CanalesAlejandro Canales
Alejandro Canales
Alzheimer’s disease (AD) is a chronic brain disorder characterized by progressive intellectual decline and memory and neuronal loss, caused mainly by extracellular deposition of amyloid-β (Aβ) and intracellular accumulation of hyperphosphorylated tau protein, primarily in areas implicated in memory and learning as prefrontal cortex and hippocampus. There are two forms of AD, a late-onset form that affects people over 65 years old, and the early-onset form, which is hereditable and affect people at early ages ~45 years. To date, there is no cure for the disease; consequently, it is essential to develop new tools for the study of processes implicated in the disease. Currently, in vitro AD three-dimensional (3D) models using induced pluripotent stem cells (iPSC)-derived neurons have broadened the horizon for in vitro disease modeling and gained interest for mechanistic studies and preclinical drug discovery due to their potential advantages in providing a better physiologically relevant information and more predictive data for in vivo tests. Therefore, this study aimed to establish a 3D cell culture model of AD in vitro using iPSCs carrying the A246E mutation. We generated human iPSCs from fibroblasts from a patient with AD harboring the A246E mutation in the PSEN1 gene. Cell reprogramming was performed using lentiviral vectors with Yamanaka’s factors (OSKM: Oct4, Sox2, Klf4, and c-Myc). The resulting iPSCs expressed pluripotency genes (such as Nanog and Oct4), alkaline phosphatase activity, and pluripotency stem cell marker expression, such as OCT4, SOX2, TRA-1-60, and SSEA4. iPSCs exhibited the ability to differentiate into neuronal lineage in a 3D environment through dual SMAD inhibition as confirmed by Nestin, MAP2, and Tuj1 neural marker expression. These iPSC-derived neurons harbored Aβ oligomers confirmed by Western Blot (WB) and immunostaining. With human iPSC-derived neurons able to produce Aβ oligomers, we established a novel human hydrogel-based 3D cell culture model that recapitulates Aβ aggregation without the need for mutation induction or synthetic Aβ exposure. This model will allow the study of processes implicated in disease spread throughout the brain, the screening of molecules or compounds with therapeutic potential, and the development of personalized therapeutic strategies.

11 September 2022 in Life
Verified
Journal Article
Open access
PDF file
DODoddy Denise Ojeda-Hernández
Doddy Denise Ojeda-Hernández
MHMercedes Azucena Hernandez-Sapiens
Mercedes Azucena Hernandez-Sapiens
EREdwin Estefan Reza-Zaldivar
Edwin Estefan Reza-Zaldivar
Alejandro CanalesAlejandro Canales
Alejandro Canales
Jordi A. Matias-GuiuJordi A. Matias-Guiu
Jordi A. Matias-Guiu
Ulises Gomez-PinedoUlises Gomez-Pinedo
Ulises Gomez-Pinedo
Current efforts to find novel treatments that counteract multiple sclerosis (MS) have pointed toward immunomodulation and remyelination. Currently, cell therapy has shown promising potential to achieve this purpose. However, disadvantages such as poor survival, differentiation, and integration into the target tissue have limited its application. A series of recent studies have focused on the cell secretome, showing it to provide the most benefits of cell therapy. Exosomes are a key component of the cell secretome, participating in the transfer of bioactive molecules. These nano-sized vesicles offer many therapeutical advantages, such as the capacity to cross the blood-brain barrier, an enrichable cargo, and a customizable membrane. Moreover, integrating of biomaterials into exosome therapy could lead to new tissue-specific therapeutic strategies. In this work, the use of exosomes and their integration with biomaterials is presented as a novel strategy in the treatment of MS.

7 September 2024 in Acta Biomaterialia
Verified
Journal Article
Open access
DODoddy Denise Ojeda-Hernández
Doddy Denise Ojeda-Hernández
SVSusana Velasco-Lozano
Susana Velasco-Lozano
Jose M. FraileJose M. Fraile
Jose M. Fraile
Juan Carlos Mateos-DíazJuan Carlos Mateos-Díaz
Juan Carlos Mateos-Díaz
FPFRANCISCO JAVIER ROJO PEREZ
FRANCISCO JAVIER ROJO PEREZ
Ulises Gomez-PinedoUlises Gomez-Pinedo
Ulises Gomez-Pinedo
Cell therapy is a promising strategy for treating neurological pathologies but requires invasive methods to bypass the blood-brain barrier restrictions. The nose-to-brain route has been presented as a direct and less invasive alternative to access the brain. The primary limitations of this route are low retention in the olfactory epithelium and poor cell survival in the harsh conditions of the nasal cavity. Thus, using chitosan-based hydrogel as a vehicle is proposed in this work to overcome the limitations of nose-to-brain cell administration. The hydrogel's design was driven to achieve gelification in response to body temperature and a mucosa-interacting chemical structure biocompatible with cells. The hydrogel showed a 95% biocompatibility with 2D and 3D cultures of mesenchymal stromal cells. Additionally, the viability, stability, and migration capacity of oligodendrocyte precursor cells (OPCs) within the hydrogel were maintained in vitro for up to 72 hours. After the intranasal administration of the OPCs-containing hydrogel, histological analysis showed the presence of viable cells in the nasal cavity for up to 72 hours post-administration in healthy athymic mice. These results demonstrate the hydrogel's capacity to increase the residence time in the nasal cavity while providing the cells with a favorable environment for their viability. This study presents for the first time the use of thermosensitive hydrogels in nose-to-brain cell therapy, opening the possibility of increasing the delivery efficiency in future approaches in translational medicine. STATEMENT OF SIGNIFICANCE: : This work highlights the potential of biomaterials, specifically hydrogels, in improving the effectiveness of cell therapy administered through the nose. The nose-to-brain route has been suggested as a non-invasive way to directly access the brain. However, delivering stem cells through this route poses a challenge since their viability must be preserved and cells can be swept away by nasal mucus. Earlier attempts at intranasal cell therapy have shown low efficiency, but still hold promise to the future. The hydrogels designed for this study can provide stem cells with a biocompatible environment and adhesion to the nasal atrium, easing the successful migration of viable cells to the brain.